Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
A legfontosabb adatok
- Ki végzi
- R-Pharm International, LLC
- Hol
- Oroszország14 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 71 fő, tervezett
- Kezdés
- 2023. márc. 17.
- Várható befejezés
- 2030. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- OKZ q4w
- A regiszteradat frissítve
- 2026. április 8.
Ki vehet részt
- Életkor
- 2 év – 17 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Study informed consent form voluntarily and independently signed by patient legal representative
- Study assent form voluntarily and independently signed by minor study subject (patient)
- Male or female patients aged ≥12 and <18 years (cohort 1 - subgroup A) or >2 and <12 years (cohort 1 - subgroup B) or >2 and <18 years (cohort 2) at the time of screening initiation and on Day 0
- Body weight at the start of screening and on Day 0 ≥45 kg (cohort 1 - subgroup A) or ≥30 and <45 kg (cohort 1 - subgroup B) or ≥18 and <30 kg (cohort 2)
- A reliable diagnosis of juvenile idiopathic arthritis (JIA) according to the JIA International League of Associations for Rheumatology (ILAR) 1 criteria with onset before the age of 16 years:; Seropositive or seronegative polyarthritis (pJIA) ≥3 months before screening, or; Systemic JIA (sJIA) for ≥3 months before screening, provided that joint symptoms persist without active systemic manifestations for ≥3 months before screening, or; Extended oligoarticular JIA (оJIA) ≥3 months before screening
- American College of Radiology (ACR) criteria of active polyarthritis are met: 5 or more active joints at screening and on Day 0
- C-reactive protein (CRP) level on screening or in anamnesis, not associated with alternative causes of increase other than the activity of the underlying disease, ≥6 mg/l
- Intolerance or failure of methotrexate in the dose of ≥15 mg/m\^2/week (or less, in a case of documented intolerance of higher doses) for ≥3 months in medical history
Ki nem vehet részt
- Prior use of any drug that acts directly on IL-6 or IL-6R
- If methotrexate is administered - any change in dose or in a formulation within 6 weeks prior to Day 0
- Previous therapy with marketed or experimental conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying anti-rheumatic drugs (bDMARDs) within less than 5 elimination half-lives
- Use of oral steroids in the doses above 0.2 mg/kg or 10 mg/day of prednisolone daily, whatever is lower, or a change in dose within 2 weeks prior to Day 0, or use of parenteral or topical steroids within 4 weeks prior to Day 0
- Change in dose of a non-steroidal anti-inflammatory drug (NSAID) within ≤2 weeks prior to Day 0
- Vaccination with live vaccines within 6 weeks before baseline, or planned vaccination with live vaccines during the study and/or within 6 weeks after the last olokizumab administration
- Active uveitis at screening or uveitis exacerbation within 24 weeks before screening
- Active course of a disease associated with formation of intestinal diverticula, or any other symptomatic gastrointestinal disease that may increase risk of perforation; or a history of diverticulitis or perforation; or concurrent Crohn's disease or ulcerative colitis
- Concurrent heart failure New York Heart Association (NYHA) III or IV functional class
- Exclusion criteria related to concurrent diseases and conditions that may increase potential risk related to participation in the study and study drug exposure
- Exclusion criteria related to past or current infection other than tuberculosis
- Suspected or confirmed current tuberculosis (TB) infection, history of an active or latent TB infection
- Patients with Steinbrocker class IV functional impairment
- Presence of systemic autoimmune or autoinflammatory disease, except JIA, or chronic autoimmune hepatitis or diseases of the primary immunodeficiencies group
- Patients with history of macrophage activation syndrome episodes
- Known hypersensitivity to any component of the study drug
- Laboratory abnormalities (creatinine ≥1 mg/dL (88 mM) for children aged 12 or ≥1.2 mg/dL (106 mM) for children aged 13 and older; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 х upper limit normal (ULN); platelets <180,000/mm\^3; white blood count (WBC) <4000/mm\^3; neutrophils <2000/mm\^3; hemoglobin ≤80 g/L
- In patients with diabetes mellitus - HbA1c > 7% within the last 3 months (non-controlled diabetes mellitus)
- Pregnant or breast-feeding female participants or planned pregnancy
- Other protocol-defined non-inclusion criteria apply
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 2 és 17 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Oroszország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks) depending on patient's weight. Secondary objectives are to evaluate the pharmacodynamic (PD) profile, the long-term efficacy and safety of olokizumab in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years.
A vizsgálat 2 csoportja
- Arm 1: OKZ 64 mg q4wA vizsgált kezelés
SC injections q4w-Cohort 1
Kezelés: OKZ q4w
- Arm 2: OKZ 48 mg q4wA vizsgált kezelés
SC injections q4w-Cohort 2
Kezelés: OKZ q4w
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-label, Multicenter Study of the Pharmacokinetics, Efficacy and Safety of Olokizumab in Pediatric and Adolescent Patients With Active Juvenile Idiopathic Arthritis
- Kérdések a feltételekről
- Forrás: NCT07517575: ki vehet részt
- A regiszteradat frissítve
- 2026. április 8.